An AI algorithm that analyzes entire coronary arteries via OCT imaging more accurately predicts adverse events than expert analysis of target lesions.
Original Title: Artificial intelligence-based identification of thin-cap fibroatheromas and clinical outcomes: the PECTUS-AI study
Journal: European heart journal
DOI: 10.1093/eurheartj/ehaf595
AI Identifies High-Risk Plaques to Predict Outcomes
Overview
This study investigated an artificial intelligence algorithm, called OCT-AID, for its ability to predict future cardiovascular problems. The research was a secondary analysis involving 414 patients who had previously experienced a heart attack. These patients had undergone optical coherence tomography (OCT) imaging of their coronary arteries. The AI and a core laboratory of human experts independently analyzed these images to detect high-risk plaques known as thin-cap fibroatheromas (TCFA). The presence of AI-identified TCFA in a target lesion was significantly associated with adverse outcomes over two years (Hazard Ratio 1.99), whereas the association for expert-identified TCFA was not statistically significant. The study aimed to validate the AI’s prognostic value against the expert standard.
Novelty
While experts have linked TCFA to poor outcomes, manual analysis is slow and variable. This study’s novelty is in evaluating a fully automated AI for this task and comparing it to the expert standard. A key finding was that analyzing the entire imaged artery with AI provided much stronger risk prediction (Hazard Ratio 5.50) than analyzing only the target lesion. This comprehensive vessel-wide assessment is practically unfeasible for manual expert analysis, highlighting a distinct advantage of the automated approach. The system demonstrated superior discriminatory ability for outcomes when analyzing the full vessel compared to the core lab’s analysis of the target lesion (C-statistics 0.66 vs. 0.56).
My Perspective
I find the relationship between the AI and the expert analysis particularly noteworthy. The study reported only fair to moderate agreement between the two, which might initially seem like a weakness of the AI. However, the AI’s predictions were more strongly associated with actual patient outcomes. This suggests the AI may be identifying subtle, yet prognostically critical, features that are not consistently captured by human interpretation. The AI’s strength is not just in mimicking human experts but in its exhaustive, frame-by-frame analysis of the entire vessel, free from fatigue or bias. This capability may allow it to establish a more direct and reliable link between plaque characteristics and clinical risk, potentially redefining the “ground truth” from expert opinion to patient outcome.
Potential Clinical / Research Applications
In a clinical setting, this technology could be integrated into cardiac catheterization labs to provide real-time, objective risk stratification. An automated analysis could help physicians make immediate decisions about treating non-flow-limiting plaques that are identified as high-risk. The algorithm’s high negative predictive value (97.6% for full-segment analysis) is especially valuable, as it could reliably identify patients who are at very low risk of future events, thereby avoiding unnecessary procedures. For research, this tool offers a standardized and reproducible method for plaque quantification. This can reduce variability in clinical trials, making them more powerful and efficient. It also facilitates large-scale analysis of entire coronary arteries, which could lead to the discovery of new imaging biomarkers for cardiovascular disease.